NZ: Pharmac to fund new Hep C treatment

This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.

Up to 50,000 people are expected to benefit from the funding of a new treatment for those with hepatitis C.

That’s the number of New Zealanders estimated to have the blood-borne disease that’s transmitted mainly through intravenous needles or badly sterilised medical equipment.

Hepatitis C targets the liver and can be fatal. Drug-buyer Pharmac today announced that from February it’ll fund the drug Maviret for those with hepatitis C regardless of the type of the virus they have.

There are six genotypes of the virus. Currently, just two drugs are funded: Viekira Pak for those with type one, and Harvoni for end stage liver disease involving all types.

Pharmac says about 3000 people have got the latter two drugs since they were funded in 2016, but an estimated 24,000 others have been without a funded treatment.

Operations director Lisa Williams said: “Maviret provides an option for those people who weren’t able to access a funded treatment previously due to their genotype of hepatitis C.”

Funding Maviret meant that most people with hepatitis C will now have the opportunity to access a funded treatment that had the potential to cure hepatitis C.

“In many instances, this treatment will avoid associated liver cancer, the need for a liver transplant or early death. Access to this drug is a significant advancement in treatment,” Ms Williams said.

She added that using all those medicines could make a real difference to the community, but added that there was a need to reach out to people who were not yet aware they have the disease.

“While this funding decision is a major step forward, an estimated 50 percent of people who have hepatitis C have not yet been diagnosed and may not even suspect they have it,” Ms Williams said.

She added that under the changes, Viekira Pak – currently funded as a first-line treatment for those with type one – will no longer be funded from February 1 next year. However, those who have already begun treatment on it will be able to complete their treatment.